2013 ICD-9-CM Diagnosis Code 205.0
Myeloid leukemia acute
- acute leukemia arising from myeloid tissue in which the granular, polymorphonuclear leukocytes and their precursors predominate.
- leukemia commonly occurring after alkylating agent treatment; manifestations include pancytopenia, megaloblastic bone marrow, and nucleated red cells in peripheral marrow; patients usually have chromosomal abnormalities in marrow cells.
- A quickly progressing disease in which too many immature blood-forming cells are found in the blood and bone marrow.
- A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification). (WHO, 2001)
- A type of acute myeloid leukemia, a quickly progressing disease in which too many immature blood-forming cells are found in the blood and bone marrow.
- An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the t(15;17)(q22;q12) translocation. There are two variants: the typical and micro granular (hypo granular) variant. This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO, 2001) -- 2003
- There are 3 ICD-9-CM codes below 205.0 that define this diagnosis in greater detail. Do not use this code on a reimbursement claim.
205.0 Excludes 
)Applies To
ICD-9-CM Volume 2 Index entries containing back-references to 205.0:
blastic (M9801/3) 
granulocytic (M9861/3) 
